PMID- 25522986
OWN - NLM
STAT- MEDLINE
DCOM- 20150415
LR  - 20220318
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
VI  - 224
DP  - 2015
TI  - HDL biogenesis, remodeling, and catabolism.
PG  - 53-111
LID - 10.1007/978-3-319-09665-0_2 [doi]
AB  - In this chapter, we review how HDL is generated, remodeled, and catabolized in 
      plasma. We describe key features of the proteins that participate in these 
      processes, emphasizing how mutations in apolipoprotein A-I (apoA-I) and the other 
      proteins affect HDL metabolism. The biogenesis of HDL initially requires 
      functional interaction of apoA-I with the ATP-binding cassette transporter A1 
      (ABCA1) and subsequently interactions of the lipidated apoA-I forms with 
      lecithin/cholesterol acyltransferase (LCAT). Mutations in these proteins either 
      prevent or impair the formation and possibly the functionality of HDL. Remodeling 
      and catabolism of HDL is the result of interactions of HDL with cell receptors 
      and other membrane and plasma proteins including hepatic lipase (HL), endothelial 
      lipase (EL), phospholipid transfer protein (PLTP), cholesteryl ester transfer 
      protein (CETP), apolipoprotein M (apoM), scavenger receptor class B type I 
      (SR-BI), ATP-binding cassette transporter G1 (ABCG1), the F1 subunit of ATPase 
      (Ecto F1-ATPase), and the cubulin/megalin receptor. Similarly to apoA-I, 
      apolipoprotein E and apolipoprotein A-IV were shown to form discrete HDL 
      particles containing these apolipoproteins which may have important but still 
      unexplored functions. Furthermore, several plasma proteins were found associated 
      with HDL and may modulate its biological functions. The effect of these proteins 
      on the functionality of HDL is the topic of ongoing research.
FAU - Zannis, Vassilis I
AU  - Zannis VI
AD  - Molecular Genetics, Whitaker Cardiovascular Institute, Boston University School 
      of Medicine, Boston, MA, 02118, USA, vzannis@bu.edu.
FAU - Fotakis, Panagiotis
AU  - Fotakis P
FAU - Koukos, Georgios
AU  - Koukos G
FAU - Kardassis, Dimitris
AU  - Kardassis D
FAU - Ehnholm, Christian
AU  - Ehnholm C
FAU - Jauhiainen, Matti
AU  - Jauhiainen M
FAU - Chroni, Angeliki
AU  - Chroni A
LA  - eng
GR  - HL48739/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Biomarkers)
RN  - 0 (Lipoproteins, HDL)
SB  - IM
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Humans
MH  - Lipid Metabolism
MH  - Lipoproteins, HDL/biosynthesis/blood/chemistry/classification/*metabolism
MH  - Protein Conformation
MH  - Structure-Activity Relationship
EDAT- 2014/12/20 06:00
MHDA- 2015/04/16 06:00
CRDT- 2014/12/20 06:00
PHST- 2014/12/20 06:00 [entrez]
PHST- 2014/12/20 06:00 [pubmed]
PHST- 2015/04/16 06:00 [medline]
AID - 10.1007/978-3-319-09665-0_2 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2015;224:53-111. doi: 10.1007/978-3-319-09665-0_2.